
    
      This is an enriched enrollment, randomized withdrawal study with an open label,
      dose-titration period followed by a randomized, double-blind, placebo-control treatment of
      twelve weeks. During the double-blind treatment period, this study will evaluate the
      analgesic effect of NKTR-181 versus placebo in patients with moderate to severe chronic low
      back pain.
    
  